Comparing Apellis Pharmaceuticals (APLS) and The Competition

Apellis Pharmaceuticals (NASDAQ: APLS) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Apellis Pharmaceuticals to similar companies based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Apellis Pharmaceuticals and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apellis Pharmaceuticals 0 0 4 0 3.00
Apellis Pharmaceuticals Competitors 172 845 1855 61 2.62

Apellis Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 80.60%. As a group, “Biopharmaceuticals” companies have a potential upside of 3.10%. Given Apellis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Apellis Pharmaceuticals is more favorable than its competitors.

Earnings and Valuation

This table compares Apellis Pharmaceuticals and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Apellis Pharmaceuticals N/A -$27.12 million -18.69
Apellis Pharmaceuticals Competitors $631.32 million $62.30 million 94.31

Apellis Pharmaceuticals’ competitors have higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

1.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.1% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


This table compares Apellis Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals N/A N/A N/A
Apellis Pharmaceuticals Competitors -13,490.78% -54.37% -24.83%

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit